Jamaica – Ganja Growers Optimistic with US Reclassification  – NY Carib News

Jamaica’s cannabis industry is cautiously optimistic following a major policy shift in the United States, with stakeholders warning that while new opportunities are emerging, the risks of being left behind are just as real.

The recent decision by the U.S. Department of Justice to reclassify certain cannabis products under federal law has been welcomed by local growers. However, industry leaders say Jamaican producers must move quickly to remain competitive in a rapidly evolving global market.

Maurice Ellis, who leads the Ganja Growers’ Association of Jamaica, described the move as a turning point for the international cannabis trade.

“Schedule III status in the United States reduces research barriers, improves access to banking, and legitimizes cannabis as a recognized medical commodity,” Ellis explained. He noted that the shift is likely to accelerate product development, clinical research, and cross-border partnerships.

For Jamaica, that could translate into increased demand for high-quality, compliant, and traceable cannabis, particularly in the medicinal and export markets. But Ellis cautioned that the benefits will not come automatically.

“U.S. operators will now have greater access to capital, tax relief, and institutional scale,” he said. “That means faster consolidation, stronger supply chains, and lower production costs.”

He warned that many Jamaican farmers, especially small and traditional growers, are not yet structured to compete at that level, leaving them vulnerable as the industry becomes more sophisticated.

“The global market is about to professionalize rapidly, and Jamaica is behind on regulatory efficiency and farmer inclusion,” Ellis added. “Local farmers risk being squeezed out before they can participate.”

Government officials, while welcoming the development, also urged a measured interpretation of the U.S. policy shift.

Delano Seiveright, Minister of State in the Ministry of Industry, Investment and Commerce, emphasized that the reclassification, from Schedule I to Schedule III, does not mean full legalization in the United States.

“Cannabis remains illegal at the federal level, and several restrictions still apply, including those related to interstate trade and broader commercial activity,” he said.

The reclassification order, signed by Acting U.S. Attorney General Todd Blanche, places marijuana in the same regulatory category as certain prescription medications, including some pain treatments and controlled substances like ketamine. While the move aligns federal policy more closely with many state laws, it does not legalize recreational use nationwide or remove cannabis from the controlled substances list.

Still, the policy shift is expected to ease regulatory burdens, expand research opportunities, and improve access to financing for legitimate operators in the U.S. market.

“These actions will enable more targeted, rigorous research into marijuana’s safety and efficacy,” Blanche said, adding that the process toward broader reclassification is ongoing, with further hearings expected.

The initiative to revisit marijuana’s classification began under the administration of former U.S. President Joe Bidenand is now continuing under current leadership.

Seiveright noted that Jamaica has been strengthening its own regulatory framework in anticipation of global changes, including reforms to licensing and expanded access within the medicinal cannabis sector.

“We are not standing still,” he said, adding that efforts are underway to ensure Jamaica is positioned to benefit from emerging opportunities in the global cannabis industry.

As the international market shifts, the message from both industry leaders and policymakers is clear: Jamaica has potential, but timing and preparedness will determine whether it capitalizes on the moment, or gets left behind.

[mc4wp_form]

By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.